US 12,240,892 B2
Pharmaceutical composition comprising expression or activity inhibitor of c-src for preventing or treating synucleinopathy
Sang Myun Park, Suwon-si (KR); Yu Ree Choi, Suwon-si (KR); and Jae Bong Kim, Busan (KR)
Assigned to AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Suwon-si (KR)
Filed by AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Suwon-si (KR)
Filed on Dec. 7, 2020, as Appl. No. 17/113,630.
Application 17/113,630 is a continuation in part of application No. PCT/KR2019/006870, filed on Jun. 7, 2019.
Claims priority of application No. 10-2018-0066005 (KR), filed on Jun. 8, 2018.
Prior Publication US 2021/0101966 A1, Apr. 8, 2021
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61P 25/28 (2006.01); C12N 15/113 (2010.01)
CPC C07K 16/18 (2013.01) [A61K 39/00 (2013.01); A61P 25/28 (2018.01); C12N 15/113 (2013.01); A61K 2039/505 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A composition for inhibiting aggregation and/or migration of α-syn comprising an inhibitor for expression of a c-src protein, wherein the inhibitor for expression of a c-src protein is a shRNA comprising the nucleotide sequence of SEQ ID NO: 1.